srd-18 Antibody

What are the primary considerations when selecting an antibody for therapeutic development?

When selecting an antibody for therapeutic development, researchers should evaluate several critical parameters. First, binding affinity to the target antigen must be high enough to achieve therapeutic effect at reasonable doses. Second, specificity must be thoroughly assessed to avoid off-target effects. Third, physical properties such as solubility, stability, and viscosity significantly impact manufacturability and administration route options. Fourth, pharmacokinetic properties like half-life directly influence dosing frequency and bioavailability .

The development of antibodies like 5A6CCS1 demonstrates how these factors interrelate. This antibody was optimized for both neutralizing capacity against SARS-CoV-2 variants and physicochemical properties to enable high-concentration formulation for subcutaneous injection, enhancing clinical utility beyond mere target binding .

How do complementarity-determining regions (CDRs) affect antibody function?

Complementarity-determining regions (CDRs) are the most variable portions of an antibody that form the antigen-binding site and directly determine binding specificity and affinity. These hypervariable loops within the variable domains of both heavy and light chains create a unique three-dimensional structure that complements the target epitope .

Systematic engineering of CDRs can substantially improve antibody performance. For example, in the development of 5A6CCS1, researchers systematically mutated CDRs by substituting each position with 18 different amino acids (excluding cysteine). Through this comprehensive approach, they identified 37 single mutations across 13 positions that enhanced binding affinity to the SARS-CoV-2 receptor binding domain (RBD). This demonstrates how precisely modifying CDRs can rescue neutralizing efficacy against escape variants while maintaining the original epitope targeting .

What methods are used to characterize antibody-antigen interactions?

Multiple complementary techniques are essential for thorough characterization of antibody-antigen interactions:

• Binding assays: ELISA, surface plasmon resonance (SPR), and bio-layer interferometry measure binding kinetics and affinity constants

• Structural analysis: X-ray crystallography and cryo-electron microscopy provide atomic-level insights into binding interfaces

• Epitope mapping: Various approaches including mutagenesis studies, peptide arrays, and competition assays

• Spectroscopic methods: Saturation transfer difference NMR (STD-NMR) can define glycan-antigen contact surfaces

• Functional assays: Neutralization assays for therapeutic antibodies against pathogens

For complex targets like carbohydrate antigens, researchers have developed combined approaches. For instance, the TKH2 antibody against tumor-associated carbohydrate antigen sialyl-Tn was characterized using a multi-faceted strategy that integrated quantitative glycan microarray screening, site-directed mutagenesis to identify key residues in the antibody combining site, and STD-NMR to define the glycan-antigen contact surface .

What strategies can improve antibody cross-reactivity against variant targets?

Enhancing antibody cross-reactivity against variant targets requires sophisticated engineering approaches targeting conserved epitopes. One effective strategy involves directed evolution combined with rational design. For example, ADG-2 was developed through affinity maturation to recognize a highly conserved epitope that overlaps the receptor binding site across multiple sarbecoviruses .

The process typically involves:

• Identifying a parent antibody with some cross-reactive potential

• Comprehensive mutagenesis of CDRs and framework regions

• Screening against multiple variants simultaneously

• Iterative combination of beneficial mutations

• Structural analysis to understand the molecular basis of cross-reactivity

This approach yielded impressive results with ADG-2, which demonstrates potent neutralization across SARS-CoV, SARS-CoV-2, and bat SARS-like viruses (SHC014 and WIV-1), with IC₅₀ values between 1-8 ng/ml . The key is targeting evolutionarily constrained epitopes that viruses cannot easily mutate without compromising fitness.

How can antibody pharmacokinetics be engineered to optimize therapeutic efficacy?

Engineering antibody pharmacokinetics involves modifying multiple parameters to achieve desired half-life, tissue distribution, and administration route compatibility. Several specific approaches have demonstrated success:

The development of 5A6CCS1 exemplifies successful integration of multiple approaches. By combining pI reduction with enhanced FcRn binding (through ACT3 mutations), researchers achieved a remarkable 4.3-fold improvement in clearance compared to the parent antibody. Additionally, optimizing the variable region improved solubility and reduced viscosity, enabling high-concentration formulations suitable for subcutaneous administration, which significantly enhances clinical utility .

What computational approaches can overcome challenges in antibody-antigen complex crystallization?

When crystallization of antibody-antigen complexes proves challenging, especially with glycan targets, researchers can employ computational modeling validated by experimental data. An effective workflow includes:

• Generate multiple potential antibody-glycan complex models using computational docking

• Experimentally define key features through:

  • Quantitative glycan microarray screening to determine apparent Kᴅ values

  • Site-directed mutagenesis to identify crucial residues in the antibody combining site

  • STD-NMR to map the glycan-antigen contact surface

• Use these experimental metrics to select the optimal 3D model from thousands of candidates

• Validate the model with additional binding studies

This approach was successfully applied to characterize the TKH2 antibody against the tumor-associated carbohydrate antigen sialyl-Tn (STn), allowing researchers to define the structural basis of binding without requiring crystal structures . The integration of high-throughput experimental techniques with computational modeling provides a generalizable solution for characterizing challenging antibody-glycan interactions.

How should neutralization potency be assessed for therapeutic antibodies targeting viral pathogens?

Comprehensive assessment of neutralization potency requires multiple complementary assays to ensure robust characterization:

• Pseudovirus neutralization assays: Allow testing against multiple variants in BSL-2 settings

  • Example: MLV-SARS-CoV-2 pseudovirus system used to screen ADG-2

• Authentic virus neutralization: Essential for confirming activity against intact pathogens

  • Example: Testing against SARS-CoV-2-nLuc, SARS-CoV, SHC014-nLuc, and WIV-1-nLuc

• Cross-neutralization assessment: Testing against related pathogens to determine breadth

  • Example: ADG-2 displayed 4-8 ng/ml IC₅₀ values against bat SARS-like viruses

• Variant testing: Evaluating activity against emerging variants of concern

  • Example: Confirming ADG-2 neutralizes the D614G variant

• In vivo protection studies: Animal models to validate protective efficacy

  • Example: ADG-2 provided complete protection against respiratory burden, viral replication in lungs, and lung pathology in mouse models of SARS and COVID-19

This multi-layered approach provides comprehensive characterization of neutralization potency and breadth, critical for therapeutic antibodies targeting viruses with significant variant diversity.

What is the optimal workflow for engineered antibody variant screening?

An efficient workflow for engineered antibody variant screening balances throughput with depth of characterization:

Stage 1: Primary Screening

• Binding affinity assays (ELISA, BLI)

• Expression level assessment

• Basic biophysical characterization (SEC analysis)

Stage 2: Secondary Screening

• Functional assays (e.g., neutralization for antiviral antibodies)

• Extended biophysical characterization (thermal stability, aggregation propensity)

• Initial manufacturability assessment

Stage 3: Detailed Characterization of Lead Candidates

• In vivo pharmacokinetics (transgenic mouse models, NHP studies)

• Comprehensive specificity profiling (cross-reactivity panels)

• Advanced manufacturability assessment

The development of 5A6CCS1 exemplifies this approach. Researchers first screened approximately 1,200 mutations for enhanced binding affinity. Promising variants were then assessed by size-exclusion chromatography to exclude those with increased high molecular weight species or abnormal column retention time. Following combination of beneficial mutations, the top candidates underwent pharmacokinetic assessment in both human FcRn transgenic mice and cynomolgus monkeys, along with virus neutralization assays and manufacturability assessment .

How can immunogenicity risk be minimized during antibody engineering?

Minimizing immunogenicity risk during antibody engineering requires a multi-faceted approach:

• Sequence assessment: Use in silico tools to identify potential T-cell epitopes and remove them through deimmunization

• Germline humanization: Align framework regions closely with human germline sequences while maintaining binding properties

• Conservative mutation selection: When introducing affinity-enhancing mutations, prefer amino acids with similar physicochemical properties to minimize immunogenicity risk

• Experimental validation: Test lead candidates with in vitro immunogenicity assays such as dendritic cell activation and T-cell proliferation assays

• Stress testing: Expose antibodies to conditions that might reveal aggregation-prone regions that could enhance immunogenicity

The development of 5A6CCS1 incorporated immunogenicity risk assessment as an integral part of the engineering process. After identifying beneficial mutations in the CDRs and framework regions, researchers evaluated their immunogenicity potential and selected those that minimized this risk while achieving the desired affinity improvements .

How might therapeutic antibodies be applied in treating complex disorders like schizophrenia?

Recent research has identified immune system involvement in subsets of patients with schizophrenia-related disorders (SRD), opening potential avenues for targeted antibody therapies. Specifically, approximately one-third of persons with SRD have elevated anti-gliadin IgG antibodies (AGA+), and this subgroup exhibits a higher burden of negative symptoms, which are notoriously treatment-resistant .

Research has demonstrated that in AGA+ SRD patients, T cell dysfunction correlates with symptom severity. Regulatory T cells (Tregs) show a protective effect against negative symptoms, while other T cell populations may drive symptom severity. This suggests that antibodies targeting specific immune pathways might provide therapeutic benefit:

• Potential antibody therapies could target pro-inflammatory cytokines that are elevated in AGA+ SRD patients, such as IL-1B, IL-2, IL-13, CCL17, and CCL28

• Antibodies that enhance Treg function or expansion could potentially alleviate negative symptoms in this patient subgroup

• Targeted antibody therapies against specific T cell subpopulations driving inflammation may provide precision treatment approaches

The correlation between specific T cell populations and symptom domains (e.g., anhedonia, alogia, avolition) suggests that tailored immunotherapeutic approaches could address specific symptom clusters based on individual patient immune profiles .

What are the considerations for developing antibodies against emerging pandemic threats?

Developing antibodies against emerging pandemic threats requires specific considerations to ensure effectiveness against both current and future pathogens:

• Target conserved epitopes: Focus on evolutionarily constrained regions that are less likely to mutate. ADG-2 exemplifies this approach by targeting a highly conserved epitope that overlaps the receptor binding site across multiple sarbecoviruses

• Balance breadth and potency: Engineer antibodies that maintain high potency while expanding neutralization breadth. ADG-2 achieves IC₅₀ values between 4-8 ng/ml against multiple sarbecoviruses

• Optimize administration routes: Develop formulations compatible with practical delivery methods during public health emergencies. 5A6CCS1 was engineered for high-concentration subcutaneous administration, enhancing accessibility during pandemics

• Consider effector functions: Engineer Fc regions for appropriate effector functions while avoiding antibody-dependent enhancement of infection. The SG1095 mutation set reduces binding affinity against human FcγRs while maintaining C1q binding

• Proactive testing against pre-emergent pathogens: Evaluate antibodies against zoonotic viruses with pandemic potential before they emerge in humans. ADG-2 was tested against bat SARS-like viruses (SHC014 and WIV-1) that can replicate in human airway cells

This approach prioritizes development of broad-spectrum therapeutics that can protect against both established and pre-emergent pathogens, creating a proactive rather than reactive pandemic response.

What emerging technologies are transforming antibody engineering?

The field of antibody engineering continues to evolve rapidly through integration of multiple technological advances:

• Comprehensive mutagenesis approaches: Systematic engineering of variable regions, as demonstrated in the development of 5A6CCS1, where approximately 2,000 variants were created by systematically mutating CDRs and frameworks, enabling thorough exploration of sequence space

• Integrated computational-experimental pipelines: Combined approaches that use experimental data to validate computational models, as shown in the characterization of TKH2, where high-throughput techniques defined antibody specificity and structure without crystallization

• Rational design targeting conserved epitopes: Structure-guided engineering to target invariant regions, exemplified by ADG-2 which recognizes a highly conserved epitope that serves as an "Achilles' heel" for clade 1 sarbecoviruses

• Multi-parameter optimization: Simultaneous engineering for affinity, specificity, physicochemical properties, and pharmacokinetics in a single development campaign rather than sequential optimization

These advances are transforming therapeutic antibody development from a primarily discovery-driven process to a rational engineering approach that can predictably create antibodies with desired properties for specific clinical applications and pandemic preparedness.